NZ598426A - Use of antisecretory factors for treating intraocular hypertension - Google Patents

Use of antisecretory factors for treating intraocular hypertension

Info

Publication number
NZ598426A
NZ598426A NZ598426A NZ59842607A NZ598426A NZ 598426 A NZ598426 A NZ 598426A NZ 598426 A NZ598426 A NZ 598426A NZ 59842607 A NZ59842607 A NZ 59842607A NZ 598426 A NZ598426 A NZ 598426A
Authority
NZ
New Zealand
Prior art keywords
intraocular hypertension
antisecretory factors
treating intraocular
treating
antisecretory
Prior art date
Application number
NZ598426A
Other languages
English (en)
Inventor
Hans-Arne Hansson
Stefan Lange
Eva Jennische
Original Assignee
Lantmannen As Faktor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantmannen As Faktor Ab filed Critical Lantmannen As Faktor Ab
Publication of NZ598426A publication Critical patent/NZ598426A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NZ598426A 2006-04-27 2007-04-27 Use of antisecretory factors for treating intraocular hypertension NZ598426A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0600932 2006-04-27
NZ572255A NZ572255A (en) 2006-04-27 2007-04-27 Use of antisecretory factors for treating intraocular hypertension

Publications (1)

Publication Number Publication Date
NZ598426A true NZ598426A (en) 2012-08-31

Family

ID=38561776

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ598426A NZ598426A (en) 2006-04-27 2007-04-27 Use of antisecretory factors for treating intraocular hypertension
NZ572255A NZ572255A (en) 2006-04-27 2007-04-27 Use of antisecretory factors for treating intraocular hypertension

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ572255A NZ572255A (en) 2006-04-27 2007-04-27 Use of antisecretory factors for treating intraocular hypertension

Country Status (18)

Country Link
US (2) US8207296B2 (cg-RX-API-DMAC10.html)
EP (2) EP2015767B1 (cg-RX-API-DMAC10.html)
JP (2) JP5284948B2 (cg-RX-API-DMAC10.html)
KR (1) KR20090040404A (cg-RX-API-DMAC10.html)
CN (2) CN101432013B (cg-RX-API-DMAC10.html)
AU (1) AU2007244004B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0710959B8 (cg-RX-API-DMAC10.html)
CA (2) CA2771087C (cg-RX-API-DMAC10.html)
DK (2) DK2015767T3 (cg-RX-API-DMAC10.html)
ES (2) ES2773945T3 (cg-RX-API-DMAC10.html)
IL (1) IL194773A (cg-RX-API-DMAC10.html)
MX (1) MX2008013769A (cg-RX-API-DMAC10.html)
NZ (2) NZ598426A (cg-RX-API-DMAC10.html)
PL (2) PL2015767T3 (cg-RX-API-DMAC10.html)
RU (1) RU2458703C2 (cg-RX-API-DMAC10.html)
SG (1) SG171602A1 (cg-RX-API-DMAC10.html)
WO (1) WO2007126364A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200809115B (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171602A1 (en) * 2006-04-27 2011-06-29 Lantmaennen As Faktor Ab Use of antisecretory factors for treating intraocular hypertension
US9962424B2 (en) 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
JP5820277B2 (ja) 2009-02-11 2015-11-24 ラントメネン・アーエス−ファクトール・アーベー 細胞取込を最適化するための抗分泌性因子（ａｆ）の使用
WO2013050795A1 (en) * 2011-10-03 2013-04-11 Femtonics Kft. Use of photoactive compounds
NZ708860A (en) * 2012-12-20 2016-09-30 Lantmännen As Faktor Ab Use of antisecretory factor (af) in glioblastoma treatment
WO2017009004A1 (en) 2015-07-10 2017-01-19 Lantmännen As-Faktor Ab Process for producing egg yolk with high content of af-16
US11407796B2 (en) 2016-07-18 2022-08-09 Lantmännen As-Faktor Ab Antisecretory factor 17
WO2020002464A1 (en) 2018-06-28 2020-01-02 Lantmännen Medical Ab Antisecretory factor for use in treatment and/or prevention of acute respiratory failure
CN112770643A (zh) 2018-09-28 2021-05-07 兰特门内保健食品公司 包含麦芽化脱壳燕麦的可消耗产品
WO2020065091A1 (en) 2018-09-28 2020-04-02 Lantmännen Functional Foods Ab A consumable product comprising malted wheat
EP4125984A1 (en) 2020-03-26 2023-02-08 Lantmännen Functional Foods AB A consumable product comprising malted cereals for promoting recovery at physical activity
US20240148709A1 (en) * 2022-11-08 2024-05-09 Aisa Pharma, Inc. Methods of treating eye pain and eye disorders
WO2026099453A1 (en) 2024-11-07 2026-05-15 Lantmännen Medical Ab Af-16 or af-17 for acute treatment of brain oedema in patients with traumatic brain injury

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH682716A5 (de) 1992-01-13 1993-11-15 Christian Fricker Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5585401A (en) * 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
SE508609C2 (sv) 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
WO1997027296A1 (en) * 1996-01-26 1997-07-31 Hsc Research And Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor
SE9604251L (sv) 1996-11-20 1997-12-22 Svenska Lantmaennen Riksfoerbu Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) * 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
AU5627000A (en) * 1999-06-21 2001-02-05 Inkine Pharmaceutical Company, Inc. Angiocidin: a CYS-SER-VAL-THR-CYS-GLY specific tumor cell adhesion receptor
RU2192898C1 (ru) * 2001-08-16 2002-11-20 Московский научно-исследовательский институт глазных болезней им. Гельмгольца Способ лечения герпетического кератита с изъязвлением
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
SG171602A1 (en) * 2006-04-27 2011-06-29 Lantmaennen As Faktor Ab Use of antisecretory factors for treating intraocular hypertension
KR20090037992A (ko) * 2006-04-27 2009-04-17 란트만넨 아스-팍토르 아베 항분비 단백질의 추가적 의학 용도
PL2040734T3 (pl) * 2006-04-27 2012-04-30 Lantmaennen As Faktor Ab Białko przeciwwydzielnicze do zastosowania w leczeniu zespołu przedziału

Also Published As

Publication number Publication date
US20120283191A1 (en) 2012-11-08
WO2007126364A3 (en) 2008-03-06
DK2468292T3 (da) 2020-03-23
BRPI0710959B1 (pt) 2018-11-06
IL194773A0 (en) 2011-08-01
JP5284948B2 (ja) 2013-09-11
CA2650344C (en) 2017-10-31
RU2008146733A (ru) 2010-06-10
CA2771087A1 (en) 2007-11-08
KR20090040404A (ko) 2009-04-24
EP2468292A1 (en) 2012-06-27
PL2015767T3 (pl) 2016-05-31
MX2008013769A (es) 2009-02-03
PL2468292T3 (pl) 2020-08-24
BRPI0710959B8 (pt) 2021-05-25
CN102633863B (zh) 2014-08-06
IL194773A (en) 2015-07-30
CA2771087C (en) 2016-03-15
US8207296B2 (en) 2012-06-26
US9000125B2 (en) 2015-04-07
BRPI0710959A2 (pt) 2012-02-28
EP2468292B1 (en) 2019-12-18
CN102633863A (zh) 2012-08-15
US20090162296A1 (en) 2009-06-25
AU2007244004B2 (en) 2012-02-09
SG171602A1 (en) 2011-06-29
CN101432013B (zh) 2015-01-07
EP2468292B8 (en) 2020-02-26
WO2007126364A2 (en) 2007-11-08
NZ572255A (en) 2012-03-30
AU2007244004A1 (en) 2007-11-08
WO2007126364A8 (en) 2009-07-23
EP2015767A2 (en) 2009-01-21
JP2012153695A (ja) 2012-08-16
ES2561945T3 (es) 2016-03-01
ES2773945T3 (es) 2020-07-15
DK2015767T3 (en) 2016-02-08
EP2015767B1 (en) 2016-01-06
ZA200809115B (en) 2009-07-29
RU2458703C2 (ru) 2012-08-20
JP2009535329A (ja) 2009-10-01
CA2650344A1 (en) 2007-11-08
CN101432013A (zh) 2009-05-13

Similar Documents

Publication Publication Date Title
MX2009010378A (es) Metodos para tratar o prevenir el vomito utilizando secretagogos de hormona de crecimiento.
NZ707292A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
NZ601868A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
NZ590050A (en) Fgf21 mutants and uses thereof
NZ624533A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
NZ595063A (en) Polypeptides from neisseria meningitidis
EA200900662A1 (ru) Лечение синдрома "сухого глаза" с помощью тестостерона и прогестагена
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
MXPA04006575A (es) Amino carboxamidas sustituidas para el tratamiento de la enfermedad de alzheimer.
NZ599604A (en) Synthetic myostatin peptide antagonists
SG171602A1 (en) Use of antisecretory factors for treating intraocular hypertension
UA96573C2 (ru) Антагонисты кинина для лечения дисфункции мочевого пузыря
MX2011013972A (es) Peptido novedoso y su uso.
WO2008051496A8 (en) Use of il-1 antagonists to treat gout and pseudogout
NZ623674A (en) Vip fragments and methods of use
ZA200901342B (en) Cytokine derivatives
SG10201803541TA (en) Biologically active c-terminal arginine-containing peptides
NZ614255A (en) Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
TW200735878A (en) Pharmaceutical compositions
NZ583429A (en) Peptides and proteins capable of inhibiting and/or preventing mast cell activation
MXPA05011783A (es) Peptidos que tienen un efecto inhibidor de enzima convertidora de angiotensina.
NZ595482A (en) Method of treating osteoporosis
EP2572723A3 (en) Materials and methods for treating or preventing organophosphate exposure associated damage
NZ591825A (en) Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating fatigue
TW200806283A (en) Therapeutic methods

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 APR 2014 BY VALEA AB

Effective date: 20130404

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 APR 2017 BY 572257

Effective date: 20140408

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2018 BY VALEA AB

Effective date: 20170412

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2019 BY VALEA AB

Effective date: 20180420

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2020 BY VALEA AB

Effective date: 20190405

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200331

LAPS Patent lapsed